Result of Annual Shareholders Meeting, Agreements, FDA Approval, Scheduled … – PR Newswire (press release)

Result of Annual Shareholders Meeting, Agreements, FDA Approval, Scheduled
PR Newswire (press release)
… (Ophthotech) for the exclusive rights to market Fovista® (anti-PDGF aptamer) outside the U.S. Novartis stated that, Fovista® is being studied in combination with anti-VEGF agents for patients going through wet age-related macular degeneration (wet

and more

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment